What one share of Replimune Group holds
We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through our novel oncolytic immunotherapies. Our proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer.
Replimune Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.16 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.98 |
| Cash and investments | $2.21 |
| Debt | $1.29 |
| Book value | $1.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.55 | $0.05 | −$1.47 | — | −$2.32 |
| 2018 | — | −$3.96 | $0.03 | −$3.24 | — | −$5.61 |
| 2019 | — | −$1.33 | $0.11 | −$1.21 | — | $4.35 |
| 2020 | — | −$1.54 | $0.19 | −$1.96 | — | $5.01 |
| 2021 | — | −$1.75 | $0.05 | −$1.38 | — | $10.71 |
| 2022 | — | −$2.26 | $0.04 | −$1.62 | — | $8.69 |
| 2023 | — | −$2.99 | $0.04 | −$2.24 | — | $9.80 |
| 2024 | — | −$3.24 | $0.09 | −$2.87 | — | $6.10 |
| 2025 | — | −$3.07 | $0.08 | −$2.47 | — | $5.39 |
| 2026 | — | −$3.38 | $0.05 | −$3.07 | — | $2.01 |
Common questions about Replimune Group
How much does one share of Replimune Group earn?
Over the last 12 months, Replimune Group lost $3.16 for each share.
Does Replimune Group pay a dividend?
Replimune Group didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Replimune Group’s book value per share?
Replimune Group’s book value is $1.26 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Replimune Group have?
Each share of Replimune Group has $2.21 of cash and investments and $1.29 of debt, as of June 30, 2026.
What is Replimune Group’s free cash flow per share?
−$2.98 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Replimune Group bought back shares?
Replimune Group’s share count rose about 1766% from 2017 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.